Evaxion Biotech (EVAX) has released an update.
Evaxion Biotech A/S, operating also under the name NovVac A/S, aims to revolutionize the field of immunotherapies and vaccines through the creation of advanced software. The company has announced that its share capital consists of over 55 million shares, with no special rights assigned to any share and all being non-negotiable. Additionally, Evaxion has empowered its board to issue warrants and increase capital to incentivize key employees, without offering preemptive rights to existing shareholders.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
